Loading...
ROCO
4114
Market cap509mUSD
Oct 08, Last price  
30.15TWD
1D
3.25%
1Q
-9.60%
Jan 2017
120.39%
IPO
255.12%
Name

Synmosa Biopharma Corp

Chart & performance

D1W1MN
ROCO:4114 chart
P/E
19.80
P/S
2.63
EPS
1.52
Div yield, %
1.84%
Shrs. gr., 5y
2.97%
Rev. gr., 5y
15.29%
Revenues
6.19b
+11.53%
2,678,901,0003,038,286,0003,234,960,0004,386,364,0005,140,495,0005,549,549,0006,189,262,000
Net income
822m
+20.03%
47,090,000638,112,000303,860,000799,091,000594,832,000684,683,000821,849,000
CFO
412m
-47.28%
-46,115,000254,402,000454,864,000630,247,000511,929,000780,622,000411,573,000
Dividend
Jul 17, 20260.9154 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.

Key people

Li-Yu Huang
Chief Financial Officer · since 2025
Jia-Xin Zhang
Senior Vice President · since 2001
Yu-Yu Lin
Senior Vice President · since 2023
Ching-Hua Tsao
Head of Accounting · since 2023
Chien-Yao Yang
Corporate Governance Officer · since 2023
Hui-Lan Chiu
Director · since 2022
Li-Wen Huang
Director · since 2009
Chairman of the Board, General Manager · since 2007
You-Peng Zhang
Director · since 2022
Xiu-Mei Lin
Independent Director · since 2019
Xiang-Lang Liu
Independent Director · since 2003
Independent Director · since 2023
Chien-Jen Wang
Independent Director · since 2022
IPO date
Sep 09, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT